Breaks Categories: Stock Spotlights

ThursdayMay 08, 2025 3:37 pm

BioMedNewsBreaks — Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers navigate complex insurance arrangements while improving profitability, quality, and a focus on patient care. With growing interest in the healthcare technology sector, Adageis stands out as a promising investment opportunity. To view the full article,…

Continue Reading

TuesdayApr 29, 2025 12:41 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With patient enrollment underway and interim analysis expected in early 2026, the study is designed to potentially meet the stringent requirements of regulatory agencies in order to strengthen the case for HyBryte(TM) as a commercially available…

Continue Reading

TuesdayApr 29, 2025 11:25 am

BioMedNewsBreaks — Adageis Is Reshaping Patient Care Through Smart Tech

Adageis is revolutionizing healthcare with its flexible, AI-centric software solutions and ProActive Care Platform, built to eliminate administrative burdens and enable providers to focus on patients. With simplicity core to its design, the platform empowers healthcare organizations by identifying missed revenue opportunities from insurers and guiding providers to secure rightful payments. Using predictive analytics through its Patented Risk Engine (“PRE”), Adageis enhances steady cash flow by forecasting incentive payments and factoring receivables. The platform seamlessly integrates with over 90 electronic health record systems, minimizing disruption and easing the shift to value-based care. As the healthcare sector continues in this trend, Adageis…

Continue Reading

FridayApr 11, 2025 3:30 pm

BioMedNewsBreaks — Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization. With streamlined onboarding, projected growth and funding, Adageis is poised for significant expansion in the healthcare technology space, offering investors a compelling opportunity to participate in the evolving $19.27 billion healthcare AI market. To…

Continue Reading

FridayApr 04, 2025 3:38 pm

BioMedNewsBreaks — Adageis Positioned to Scale Impact in Health Technology Landscape

Adageis is a forward-thinking healthcare technology company that is transforming patient care with AI-driven software solutions. The company recently secured $2 million in seed financing and plans to utilize the funding to support upgrades to its backend infrastructure, expand Electronic Health Record (“EHR”) system connectivity, and increase sales efforts to promote rapid growth. Its flagship ProActive Care Platform assists healthcare providers in the transition to value-based care, improving patient focus, reducing costs, and increasing reimbursements. Adageis’ technology seamlessly integrates with over 90 EHR systems, enabling smooth implementation without disrupting workflows. By leveraging AI, the company simplifies insurance complexities and supports the…

Continue Reading

TuesdayMar 25, 2025 2:13 pm

BioMedNewsBreaks — Adageis Is Bringing AI to the Forefront of Value-Based Care

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions stand distinct in providing key competencies in several areas including risk identification and early intervention, revenue tracking and forecasting, clinical decision support, administrative task automation, and continuous patient monitoring. Adageis’ platform demonstrates how AI can…

Continue Reading

FridayMar 21, 2025 2:31 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova,…

Continue Reading

FridayMar 21, 2025 12:34 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and the 37th Annual Roth Conference. At both events, Clene’s management discussed the latest achievements with CNM-Au8, a gold nanocrystal-based oral suspension that targets mitochondrial dysfunction and promotes neuronal health. The drug has shown promising results in…

Continue Reading

WednesdayMar 19, 2025 2:14 pm

BioMedNewsBreaks — Adageis Navigates Complexities of Value-Based Care with Tailored Solution

Adageis was featured in a recent article that discussed the company’s positioning as healthcare shifts toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. “While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures that can be difficult to navigate,” the article reads. “One of the major challenges in the marketplace is the sheer complexity… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance,” Adageis CEO Shane Speirs was quoted as saying.…

Continue Reading

TuesdayMar 18, 2025 12:51 pm

BioMedNewsBreaks — Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads a recent article. “With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.” To view the full article, visit https://ibn.fm/AUjKv About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing…

Continue Reading